Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/57898
Title: Exploring gastrointestinal manifestations in childhood onset systemic lupus erythematosus - Insights from a multicenter study
Authors: Sonmez, Hafize Emine
Batu, Ezgi Deniz
Isguder, Rana
Sahin, Nihal
Aliyev, Emil
Aslan, Esma
Coban, Suemeyra
Güngörer, Vildan
Karadağ, Şerife Gül
Karaçayır, Nihal
Kısaoğlu, Hakan
Yekedüz Bülbül, Aydan
Garip, Sevinç
Karalı, Yasin
Ayduran, Semra
Demir, Selcan
Kaya Akça, Ümmüşen
Başaran, Özge
Şahin, Sezgin
Kasap, Belde
Kilic, Sara Sebnem
Kışla Ekinci, Rabia Miray
Kısaarslan, Ayşenur Paç
Kalyoncu, Mukaddes
Bakkaloğlu, Sevcan
Yüksel, Selçuk
Aktay Ayaz, Nuray
Çelikel Acar, Banu
Sözeri, Betül
Kasapçopur, Özgür
Ünsal, Erbil
Özen, Seza
Keywords: Systemic lupus erythematosus
gastrointestinal system
child
autoimmune hepatitis
Clinics American-College
Damage Index
Adult-Onset
Features
Publisher: Sage Publications Ltd
Abstract: Objective Systemic lupus erythematosus (SLE) constitutes an autoimmune disorder with potential involvement of the gastrointestinal system (GIS). Our objective was to assess the gastrointestinal (GI) manifestations in patients diagnosed with childhood onset SLE.Methods The study cohort consisted of 123 patients with childhood onset-SLE and GIS involvement from 16 referral departments of pediatric rheumatology. All participants met the Systemic Lupus International Collaborating Clinics criteria.Results Out of 123 patients, 78 (63.4%) exhibited GIS involvement at the initial SLE diagnosis, whereas the remaining 45 (36.6%) developed GI symptoms after a median duration of 12 (3-140) months. Eighty-two (66.7%) individuals experienced symptoms related to the GI tract, whereas the remaining patients received a diagnosis of GI involvement through laboratory assessments. The predominant initial GIS involvement symptom was abdominal pain, observed in 77 (62.6%) patients, followed by elevated hepatic transaminases in 70 (56.9%), hepatomegaly in 40 (32.5%), diarrhea in 26 (21.1%), and jaundice in 11 (8.9%) patients. The GIS involvement was associated with SLE in 82 (78.6%), while it resulted from drug-related adverse events in 35 (28.5%) patients or comorbidities in 6 (0.5%) patients.Conclusion GIS involvement should be considered in all childhood onset-SLE patients, especially in the presence of suggestive symptoms or elevated hepatic transaminases. It is also crucial to consider SLE in the differential diagnosis of GIS manifestations in children. Apart from GIS involvement directly associated with SLE, adverse events of drugs should be kept in mind.
URI: https://doi.org/10.1177/09612033241279071
https://hdl.handle.net/11499/57898
ISSN: 0961-2033
1477-0962
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.